What it does
Cerebrolysin is genuinely interesting editorially because it is not a single compound — it is a defined mixture of low-molecular-weight neuroactive peptides and free amino acids enzymatically extracted from young porcine brain tissue, manufactured by the Austrian company EVER Pharma. It has been clinically used for over 30 years across Europe, Russia, China, and parts of Latin America for acute ischemic stroke, vascular and Alzheimer's-type dementias, and traumatic brain injury — with several adequately-sized RCTs (notably CASTA in stroke and several Alzheimer's trials). It is NOT FDA-approved in the United States. The multi-component nature makes it harder to characterize than a single-molecule drug — different batches are standardized but the active component(s) are not isolated — which is itself an unusual editorial framing in a 'peptide' library.
Used for
Dose
- Starting
- 5,000,000 mcg · once daily, courses of 10–30 days, repeated
- Common
- 27,500,000 mcg · once daily, courses of 10–30 days, repeated
- Upper
- 50,000,000 mcg · once daily, courses of 10–30 days, repeated
- When
- MorningClinic protocols dose during the morning of a cycle day. The cognitive + mood activation favors early timing — evening dosing can interfere with sleep onset.
- Site
- intramuscular or slow intravenous
Need exact volumes? Open the peptide calculator →
⚠ Caution
- Severe renal insufficiency (manufacturer warning)
- Pregnancy and breastfeeding (limited safety data)
- Active epilepsy or status epilepticus (rare reports of seizure precipitation; manufacturer warning)
- Known hypersensitivity to porcine proteins or formulation excipients
- Concurrent use with antidepressants/MAOIs requires dose reduction per manufacturer guidance
Your stack
Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.
Add to my stack